Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Pedro Ayuso, Félix Javier Jiménez-Jiménez, Javier Gómez-Tabales, Hortensia Alonso-Navarro, Elena García-Martín & José A. G. Agúndez. (2023) An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 19:7, pages 447-460.
Read now
Read now
Guiqin Liu, Xue Bai, Jianxin Yang, Yabin Duan, Junbo Zhu & Li Xiangyang. (2023) Relationship between blood–brain barrier changes and drug metabolism under high-altitude hypoxia: obstacle or opportunity for drug transport?. Drug Metabolism Reviews 55:1-2, pages 107-125.
Read now
Read now
Pedro Ayuso, Yolanda Macías, Javier Gómez-Tabales, Elena García-Martín & José A. G. Agúndez. (2022) Molecular monitoring of patient response to painkiller drugs. Expert Review of Molecular Diagnostics 22:5, pages 545-558.
Read now
Read now
Chukwunonso K. Nwabufo, Omozojie P. Aigbogun, Kevin J.H Allen, Madeline N. Owens, Jeremy S. Lee, Christopher P. Phenix & Ed S. Krol. (2021) Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds. Xenobiotica 51:8, pages 885-900.
Read now
Read now
Ramon Cacabelos. (2020) Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 5:3, pages 181-234.
Read now
Read now
Thomas Müller & Jan-Dominique Möhr. (2018) Long-term management of Parkinson’s disease using levodopa combinations. Expert Opinion on Pharmacotherapy 19:9, pages 1003-1011.
Read now
Read now
Félix Javier Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín & José A. G. Agúndez. (2016) Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 433-448.
Read now
Read now
Eleonora Džoljić, Ivana Novaković, Maja Krajinovic, Ivan Grbatinić & Vladimir Kostić. (2015) Pharmacogenetics of drug response in Parkinson's disease. International Journal of Neuroscience 125:9, pages 635-644.
Read now
Read now
Elena García-Martín, Gabriela Canto & José AG Agúndez. (2013) Metabolic considerations of drugs in the treatment of allergic diseases. Expert Opinion on Drug Metabolism & Toxicology 9:11, pages 1437-1452.
Read now
Read now
Articles from other publishers (34)
Caryl E. Sortwell, Mallory L. Hacker, David Luke Fischer, Peter E. Konrad, Thomas L. Davis, Joseph S. Neimat, Lily Wang, Yanna Song, Zach R. Mattingly, Allyson Cole-Strauss, Jack W. Lipton & P. David Charles. (2022) BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease. Neuromodulation: Technology at the Neural Interface 25:6, pages 846-853.
Crossref
Crossref
Ramón Cacabelos, Iván Carrera, Olaia Martínez, Ramón Alejo, Lucía Fernández‐Novoa, Pablo Cacabelos, Lola Corzo, Susana Rodríguez, Margarita Alcaraz, Laura Nebril, Iván Tellado, Natalia Cacabelos, Rocío Pego, Vinogran Naidoo & Juan C. Carril. (2021) Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Medicinal Research Reviews 41:5, pages 2841-2886.
Crossref
Crossref
Vladimira Vuletić, Valentino Rački, Eliša Papić & Borut Peterlin. (2021) A Systematic Review of Parkinson’s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?. International Journal of Molecular Sciences 22:13, pages 7213.
Crossref
Crossref
Xiang Li, Wenjun Wang, Jianghong Yan & Fancai Zeng. (2021) Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson’s Disease. Frontiers in Neuroscience 15.
Crossref
Crossref
Jiali Zhu & Min Chen. (2021) The effect and safety of ropinirole in the treatment of Parkinson disease. Medicine 100:46, pages e27653.
Crossref
Crossref
E.A Boonstra, M.R van Schouwenburg, A.K Seth, M Bauer, J.B Zantvoord, E.M Kemper, C.S Lansink & H.A Slagter. (2020) Conscious perception and the modulatory role of dopamine: no effect of the dopamine D2 agonist cabergoline on visual masking, the attentional blink, and probabilistic discrimination. Psychopharmacology 237:9, pages 2855-2872.
Crossref
Crossref
M. A. Cox, C. Bassi, M. E. Saunders, R. Nechanitzky, I. Morgado‐Palacin, C. Zheng & T. W. Mak. (2019) Beyond neurotransmission: acetylcholine in immunity and inflammation. Journal of Internal Medicine 287:2, pages 120-133.
Crossref
Crossref
Ehsan Khan. 2020. Understanding Pharmacology in Nursing Practice. Understanding Pharmacology in Nursing Practice
345
366
.
Andrew D. Krystal & Aric A. Prather. (2019) Sleep Pharmacogenetics. Sleep Medicine Clinics 14:3, pages 317-331.
Crossref
Crossref
Sara Redenšek, Barbara Jenko Bizjan, Maja Trošt & Vita Dolžan. (2019) Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson’s Disease. Frontiers in Genetics 10.
Crossref
Crossref
Mark Dominic Latt, Simon Lewis, Olfat Zekry & Victor S. C. Fung. (2019) Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson’s Disease. Drugs & Aging 36:3, pages 189-202.
Crossref
Crossref
Jiahong Zhong, Hui Yu, Chang Huang, Qiuping Zhong, Yaping Chen, Jinfeng Xie, Zhongzhen Zhou, Jiangping Xu & Haitao Wang. (2018) Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress. Redox Biology 16, pages 47-58.
Crossref
Crossref
Cristina Politi, Cinzia Ciccacci, Giuseppe Novelli & Paola Borgiani. (2018) Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies. NeuroMolecular Medicine 20:1, pages 1-17.
Crossref
Crossref
José L. Moreno & Javier González-Maeso. 2018. 5-HT2A Receptors in the Central Nervous System. 5-HT2A Receptors in the Central Nervous System
147
189
.
Hans-Peter Landolt, Sebastian C. Holst & Amandine Valomon. 2019. Sleep-Wake Neurobiology and Pharmacology. Sleep-Wake Neurobiology and Pharmacology
207
241
.
Saskia Müller-Rebstein, Claudia Trenkwalder, Jens Ebentheuer, Wolfgang H. Oertel, Carsten Culmsee & Günter U. Höglinger. (2017) Drug Safety Analysis in a Real-Life Cohort of Parkinson’s Disease Patients with Polypharmacy. CNS Drugs 31:12, pages 1093-1102.
Crossref
Crossref
Holger Petri. (2017) Arzneimitteltherapiesicherheit: Das Interaktionspotenzial der Dopaminagonisten. Deutsches Ärzteblatt Online.
Crossref
Crossref
Michela CampoloGiovanna CasiliFlavia BiundoRosalia CrupiMarika CordaroSalvatore CuzzocreaEmanuela Esposito. (2017) The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2. Antioxidants & Redox Signaling 27:8, pages 453-471.
Crossref
Crossref
Carlos Fernández‐Moriano, Elena González‐Burgos & Maria Pilar Gómez‐Serranillos. 2017. Neuroprotective Natural Products. Neuroprotective Natural Products
107
151
.
Jean‐Christophe Corvol & Werner Poewe. (2016) Pharmacogenetics of Parkinson's Disease in Clinical Practice. Movement Disorders Clinical Practice 4:2, pages 173-180.
Crossref
Crossref
Ireos Filipuzzi, Simona Cotesta, Francesca Perruccio, Britta Knapp, Yue Fu, Christian Studer, Verena Pries, Ralph Riedl, Stephen B. Helliwell, Katarina T. Petrovic, N. Rao Movva, Dominique Sanglard, Jianshi Tao & Dominic Hoepfner. (2016) High-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal Ergolines. PLOS Genetics 12:11, pages e1006374.
Crossref
Crossref
Joseph R. Phillips, Abeer M. Eissa, Doaa H. Hewedi, Marjan Jahanshahi, Mohamed El-Gamal, Szabolcs Keri & Ahmed A. Moustafa. (2016) Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson’s disease. Reviews in the Neurosciences 27:7, pages 729-738.
Crossref
Crossref
Nada Yousif, Richard Z. Fu, Bilal Abou-El-Ela Bourquin, Vamsee Bhrugubanda, Simon R. Schultz & Barry M. Seemungal. (2016) Dopamine Activation Preserves Visual Motion Perception Despite Noise Interference of Human V5/MT. The Journal of Neuroscience 36:36, pages 9303-9312.
Crossref
Crossref
Ting Wang, Leting Yang, Jing Hua, Huiru Xie, Xuehua Jiang & Ling Wang. (2016) Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 125, pages 280-285.
Crossref
Crossref
M. Vel?zquez-Paniagua, A.M. V?zquez-?lvarez, G. Valverde-Aguilar & P. Vergara-Arag?n. (2016) Current treatments in Parkinson's including the proposal of an innovative dopamine microimplant. Revista M?dica del Hospital General de M?xico 79:2, pages 79-87.
Crossref
Crossref
Sebastian C. HolstAmandine ValomonHans-Peter Landolt. (2016) Sleep Pharmacogenetics: Personalized Sleep-Wake Therapy. Annual Review of Pharmacology and Toxicology 56:1, pages 577-603.
Crossref
Crossref
Abdallah M. Zeid, Jenny Jeehan M. Nasr, Fathalla F. Belal, Shinya Kitagawa, Noritada Kaji, Yoshinobu Baba & Mohamed I. Walash. (2016) Determination of six anti-Parkinson drugs using cyclodextrin-capillary electrophoresis method: application to pharmaceutical dosage forms. RSC Advances 6:21, pages 17519-17530.
Crossref
Crossref
Eric R Londin, Peter Clark, Marialuisa Sponziello, Larry J Kricka, Paolo Fortina & Jason Y Park. (2015) Performance of exome sequencing for pharmacogenomics. Personalized Medicine 12:2, pages 109-115.
Crossref
Crossref
Mateusz Kurzawski, Monika Białecka & Marek Droździk. (2015) Pharmacogenetic considerations in the treatment of Parkinson's disease. Neurodegenerative Disease Management 5:1, pages 27-35.
Crossref
Crossref
Allon Goldberg, Catherine L. Curtis & Jeffrey A. Kleim. (2015) Linking Genes to Neurological Clinical Practice. Journal of Neurologic Physical Therapy 39:1, pages 52-61.
Crossref
Crossref
Etheresia Pretorius, Albe C Swanepoel, Antoinette V Buys, Natasha Vermeulen, Wiebren Duim & Douglas B Kell. (2014) Eryptosis as a marker of Parkinson's disease. Aging 6:10, pages 788-819.
Crossref
Crossref
José A. G. Agúndez, Félix J. Jiménez-Jiménez, Hortensia Alonso-Navarro & Elena GarcÃa-MartÃn. (2014) Drug and xenobiotic biotransformation in the blood–brain barrier: a neglected issue. Frontiers in Cellular Neuroscience 8.
Crossref
Crossref
Samantha M. McGraw, Donald L. Hoover & Matthew P. Shirey. (2013) Exercise Guidelines for Patients With Parkinson’s Disease. Home Health Care Management & Practice 26:3, pages 167-174.
Crossref
Crossref
Félix J. Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín & José A.G. Agúndez. (2014) COMT gene and risk for Parkinson’s disease. Pharmacogenetics and Genomics 24:7, pages 331-339.
Crossref
Crossref